Dutrebis Approval History
Dutrebis (lamivudine and raltegravir) is a fixed-dose combination of a nucleoside analog reverse transcriptase inhibitor and an integrase strand transfer inhibitor for the treatment of HIV-1 infection.
Dutrebis is NOT commercially available in the U.S.
Development History and FDA Approval Process for Dutrebis
|Feb 10, 2015||FDA Approves Dutrebis (lamivudine and raltegravir) for HIV-1 Infection|
|Jun 24, 2014||FDA Accepts Merck’s NDA for Fixed-Dose Combination of Raltegravir with Lamivudine|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.